PMN

ProMIS Neurosciences Inc.

12.71 USD

Last updated Sep 5, 11:58 UTC

Yesterday HIGH

$13.46

Yesterday LOW

$12.56

52w HIGH

$27.2

52w LOW

$6.27

EPS

-1.28

PE

-9.93

Next Earnings

Nov 11, 2026

Overview News Insider Transactions Government Trades Fundamentals

ProMIS Neurosciences Inc. stock is down -4.65% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 14 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Mon Jul 27, 2026

Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.
Benzinga Newsdesk

Tue Jul 14, 2026

ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected Soon

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteersRepresents one of the first quantitative measures of treatment-related
Benzinga Newsdesk

Wed Jul 8, 2026

Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $19.
Benzinga Newsdesk

Tue Jun 30, 2026

ProMIS Neurosciences shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.
Benzinga Insights

Tue Jun 30, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman)
Benzinga Newsdesk

Tue Jun 30, 2026

Cantor Fitzgerald Initiates Coverage On ProMIS Neurosciences with Overweight Rating

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Overweight rating.
Benzinga Newsdesk

Wed Jun 24, 2026

HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
Benzinga Newsdesk

Mon Jun 8, 2026

HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026
Benzinga Newsdesk

Tue May 12, 2026

ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of $(5.25) per share from